Table 1
Assessment and evaluation schedule of this study
| 12 Weeks before randomisation | Day 0 (Week 0) | Week 8 Week 16 | Week 24 | Week 32 Week 40 | Week 48 | |
| Diagnosed with clinical FH (pre-registration) | Randomisation (registration) | Main period | Primary endpoint | Observational period | Trial end | |
| Informed consent | X | |||||
| Patient background | X | |||||
| Check adverse events |
| |||||
| Height | X | |||||
| Body weight | X | X | X | X | X | X |
| BP/HR | X | X | X | X | X | X |
| Symptoms | X | X | X | X | X | X |
| Physical examination | X | X | X | X | X | X |
| Blood tests | ||||||
| Lipid profile | X | X | X | X | X | X |
| FPG/HbA1c | X | X | X | X | X | X |
| CBC | X | X | X | X | X | X |
| Chemistry | X | X | X | X | X | X |
| Genetic testing | X | |||||
| Lipid-lowering therapy regimen | X | X | X | X | X | X |
| PSQ-18 | X | X | X | X | ||
| Smoking status | X | X | X | X | X | X |
BP, blood pressure; CBC, complete blood counts; FH, familial hypercholesterolemia; FPG, fasting plasma glucose; HR, heart rate; PSQ-18, the Patient Satisfaction Questionnaire Short Form.